Autologous Hematopoietic Stem Cell Transplantation for Secondary Progressive Multiple Sclerosis

Richard K Burt; Basil Sharrack; Roumen Balabanov; John Rose; Xiaoqiang Han; Kathleen Quigley; Riccardo Saccardi

doi:10.1201/9781315151366-40

Autologous Hematopoietic Stem Cell Transplantation for Secondary Progressive Multiple Sclerosis

Richard K Burt, Basil Sharrack, Roumen Balabanov, John Rose, Xiaoqiang Han, Kathleen Quigley, Riccardo Saccardi

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Autologous hematopoietic stem cell transplantation (HSCT) is a form of immune suppressive/modulating therapy and, similar to other immune drugs, is largely ineffective in secondary progressive multiple sclerosis (SPMS). Future autologous HSCT studies performed in SPMS should be limited to SPMS with ongoing disease activity, have a control treatment arm, monitor brain and cervical cord atrophy, and utilize a conditioning regimen that does not increase early post-HSCT central nervous system atrophy as demonstrated on magnetic resonance (MRI).

Original language	English (US)
Title of host publication	Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases
Publisher	CRC Press
Pages	369-374
Number of pages	6
ISBN (Electronic)	9781351364768
ISBN (Print)	9781032827940
DOIs	https://doi.org/10.1201/9781315151366-40
State	Published - Jan 1 2021

ASJC Scopus subject areas

General Medicine
General Immunology and Microbiology

Access to Document

10.1201/9781315151366-40

Cite this

@inbook{07fca057cb1549ec9d3136bfc321cf19,

title = "Autologous Hematopoietic Stem Cell Transplantation for Secondary Progressive Multiple Sclerosis",

abstract = "Autologous hematopoietic stem cell transplantation (HSCT) is a form of immune suppressive/modulating therapy and, similar to other immune drugs, is largely ineffective in secondary progressive multiple sclerosis (SPMS). Future autologous HSCT studies performed in SPMS should be limited to SPMS with ongoing disease activity, have a control treatment arm, monitor brain and cervical cord atrophy, and utilize a conditioning regimen that does not increase early post-HSCT central nervous system atrophy as demonstrated on magnetic resonance (MRI).",

author = "Burt, {Richard K} and Basil Sharrack and Roumen Balabanov and John Rose and Xiaoqiang Han and Kathleen Quigley and Riccardo Saccardi",

note = "Publisher Copyright: {\textcopyright} 2022 Taylor & Francis Group, LLC.",

year = "2021",

month = jan,

day = "1",

doi = "10.1201/9781315151366-40",

language = "English (US)",

isbn = "9781032827940",

pages = "369--374",

booktitle = "Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases",

publisher = "CRC Press",

}

TY - CHAP

T1 - Autologous Hematopoietic Stem Cell Transplantation for Secondary Progressive Multiple Sclerosis

AU - Burt, Richard K

AU - Sharrack, Basil

AU - Balabanov, Roumen

AU - Rose, John

AU - Han, Xiaoqiang

AU - Quigley, Kathleen

AU - Saccardi, Riccardo

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Autologous hematopoietic stem cell transplantation (HSCT) is a form of immune suppressive/modulating therapy and, similar to other immune drugs, is largely ineffective in secondary progressive multiple sclerosis (SPMS). Future autologous HSCT studies performed in SPMS should be limited to SPMS with ongoing disease activity, have a control treatment arm, monitor brain and cervical cord atrophy, and utilize a conditioning regimen that does not increase early post-HSCT central nervous system atrophy as demonstrated on magnetic resonance (MRI).

AB - Autologous hematopoietic stem cell transplantation (HSCT) is a form of immune suppressive/modulating therapy and, similar to other immune drugs, is largely ineffective in secondary progressive multiple sclerosis (SPMS). Future autologous HSCT studies performed in SPMS should be limited to SPMS with ongoing disease activity, have a control treatment arm, monitor brain and cervical cord atrophy, and utilize a conditioning regimen that does not increase early post-HSCT central nervous system atrophy as demonstrated on magnetic resonance (MRI).

UR - http://www.scopus.com/inward/record.url?scp=85191107666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85191107666&partnerID=8YFLogxK

U2 - 10.1201/9781315151366-40

DO - 10.1201/9781315151366-40

M3 - Chapter

AN - SCOPUS:85191107666

SN - 9781032827940

SP - 369

EP - 374

BT - Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases

PB - CRC Press

ER -

Autologous Hematopoietic Stem Cell Transplantation for Secondary Progressive Multiple Sclerosis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this